Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Metrics to compare | CYBN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYBNPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.8x | −1.8x | −0.5x | |
PEG Ratio | −0.57 | 0.01 | 0.00 | |
Price/Book | 1.2x | 1.1x | 2.6x | |
Price / LTM Sales | - | 0.8x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 38.7% | |
Fair Value Upside | Unlock | 17.1% | 5.0% | Unlock |